GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (FRA:VB0) » Definitions » Valuation Rank

Viva Biotech Holdings (FRA:VB0) Valuation Rank


View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Viva Biotech Holdings Valuation Rank Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Viva Biotech Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (FRA:VB0) » Definitions » Valuation Rank
Comparable Companies
HKSE:02315 HKSE:01477 HKSE:02256 HKSE:02616 HKSE:02142 HKSE:02480 HKSE:01521 HKSE:02179 HKSE:09966 HKSE:01541 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
VBIZF:USA 01873:Hong Kong
Address
735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Website
https://www.vivabiotech.com
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation (CDMO) and commercialisation services segment include contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates, and formulations. Geographically, the company generates a majority of its revenue from the United States of America, and the rest from the European Union, Chinese Mainland, Africa, and other regions.